Company Imprimis Pharmaceuticals Inc Nasdaq

US45323A2015

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

USD in Million	2022	Weight	2023	Weight	Delta
Innovative Ophthalmic Therapies 100.0 %	89	100.0 %	130	100.0 %	+46.95%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	89	100.0 %	130	100.0 %	+46.95%

Managers	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	05-12-31
Andrew Boll DFI	Director of Finance/CFO	41	11-11-30
Jamie Webb IRC	Investor Relations Contact	-	-
Kim Barratt HRO	Human Resources Officer	-	22-06-30
Dennis E. Saadeh PRN	Corporate Officer/Principal	-	-
Mark Mannebach LAW	General Counsel	-	23-03-05
John Saharek PRN	Corporate Officer/Principal	64	12-10-31

Members of the board	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	05-12-31
Lauren Silvernail BRD	Director/Board Member	65	Jan. 25
Adrienne Graves BRD	Director/Board Member	69	Jan. 25
Teresa Sparks BRD	Director/Board Member	55	20-03-15
Perry J. Sternberg BRD	Director/Board Member	55	22-03-30
Marty Makary BRD	Director/Board Member	53	22-03-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	35,362,642	30,204,168 ( 85.41 %)	0	85.41 %

Name	Equities	%	Valuation
Opaleye Management, Inc. 10.80 %	3,820,000	10.80 %	51 M $
Opaleye Management, Inc. 10.68 %	3,775,000	10.68 %	50 M $
Private Capital Management LLC 7.902 %	2,794,497	7.902 %	37 M $
Mark Baum 6.045 %	2,137,525	6.045 %	28 M $
BlackRock Advisors LLC 5.945 %	2,102,134	5.945 %	28 M $
Daniel Kaufman 5.394 %	1,907,332	5.394 %	25 M $
Vanguard Fiduciary Trust Co. 5.114 %	1,808,552	5.114 %	24 M $
Braidwell LP 4.238 %	1,498,584	4.238 %	20 M $
Morgan Stanley Investment Management, Inc. 3.865 %	1,366,741	3.865 %	18 M $
DWS Investment Management Americas, Inc. 2.118 %	748,855	2.118 %	10 M $

Name	Equities	%	Valuation
ETON PHARMACEUTICALS, INC. 7.72%	1,982,000	7.72%	7,432,500 $

Harrow, Inc.

102 Woodmont Boulevard Suite 610

37205, Nashville

http://www.harrowinc.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals